The proliferation of a less fatal strain of Covid hurt prospects for both Pfizer (PFE) and especially Moderna (MRNA).

Pharmaceutical giant Pfizer (PFE) has named company veteran Chris Boshoff its chief of research and development (R&D) as it ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...

Recent developments in health news highlight the CDC's anticipation of increased COVID-19 and RSV cases during the holidays, ...

Pfizer has appointed Chris Boshoff, its current chief oncology officer and executive vice president, as chief scientific ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff ...

Leerink notes Pfizer (PFE) announced that Chris Boshoff will become the new Chief Scientific Officer, succeeding Mikael Dolsten. The firm views ...